Generex Biotechnology Corporation (Nasdaq: GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it is presenting study results at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD, www.easd.org) being held in Stockholm, Sweden, 20 - 24 September, 2010 (www.easd2010.com).
An abstract entitled No Generation of Insulin Antibodies in Subjects with Impaired Glucose Tolerance Treated With Buccal Spray Insulin is a poster presentation at the symposium. The abstract is authored by physicians from the Endocrinology and Diabetes Department, University "Campus Bio-Medico" and the Diabetes Department, Hospital "St. Pertini", both of Rome, Italy.
The abstract presents data from a study demonstrating that treatment with the Company's propriety buccal insulin spray product, Generex Oral-lyn™, is a valuable tool for managing hyperglycaemia in subjects with impaired glucose tolerance. "There is little doubt that the imperative for treating impaired glucose tolerance is mounting across the diabetes universe. This study adds another measure of safety to the use of buccal delivery of insulin to achieve this goal" commented Dr. Gerald Bernstein, Generex's Vice-President for Medical Affairs.
The EASD Annual Meeting, which brings together more than 14,000 delegates in the healthcare industry, is a premier platform for professional exchange in the field of diabetes. The EASD brings together scientists, physicians, laboratory workers, nurses, and students from all over the world who are interested in diabetes and related subjects.
SOURCE Generex Biotechnology Corporation